News | November 19, 2022
Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)